![FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/V6YRLBAYHY7UT2CI3WP3BBRTHA.jpg?smart=true&auth=3f2ad15f6f856acd9c684aee26a43910bec226a14ea106741c3326f7155e9c92&width=400&height=225)
Pharmaceutical company AstraZeneca has approached Gilead Sciences for a potential merger. Reuters
Pharmaceutical company AstraZeneca has approached Gilead Sciences for a potential merger. Reuters
AstraZeneca looks at merger with Gilead
Gilead has attracted investor interest because of remdesivir, the antiviral drug being tested during the Covid-19